arrow
R

Ryosuke Tateishi

the university of tokyo
H指数:71
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adipose tissue and survival among patients with advanced biliary tract cancer

脂肪组织与晚期胆道癌患者生存率的关系

2026-08-010
PRE
Real-World Evidence from a Nationwide Prospective Study of the Efficacy/Safety of Systemic Therapy for Unresectable Hepatocellular Carcinoma: First 1,000 Patients of the PRISM Study

全国性前瞻性研究中的真实世界证据:不可切除肝细胞癌系统性治疗的有效性/安全性分析——PRISM研究的前1000例患者

2026-05-010
PRE
Temporal trends and regional variations in hepatocellular carcinoma etiology: a multinational study across Asia

肝癌病因学的时间趋势和区域差异:一项跨越亚洲的多国研究

2026-02-050
OAAI
Guidance for Liver Rehabilitation in Chronic Liver Disease

慢性肝病肝脏康复指导

2026-01-310
OAAI
Machine Learning Approach Enables Highly Accurate Identification of At-Risk Metabolic Dysfunction-Associated Steatohepatitis

机器学习方法可以高度准确地识别高危代谢功能障碍相关的脂肪性肝炎

2026-01-230
OAAI
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT

阿替利珠单抗联合贝伐珠单抗用于不适合TACE治疗的超出Up-To-7标准的中间阶段肝癌:REPLACEMENT研究的最终分析

2025-11-030
OAAI
Pre-Treatment Liver Stiffness Is a Stronger Predictor of Hepatocellular Carcinoma Development Than Post-Treatment Liver Stiffness After Hepatitis C Virus Eradication

治疗前肝硬度是比治疗后肝硬度更强的预测因子,用于预测丙型肝炎病毒清除后的肝细胞癌发展。

2025-10-012
OAAI
Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis

治疗前血清血管生成素-2可预测接受索磷布韦和韦帕他韦成功清除HCV后,HCV相关失代偿期肝硬化患者的预后及肝脏功能储备

2025-06-200
PRE
Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma

亚洲肿瘤消融会议肝细胞癌指南

2025-03-030
OA